prevention of discontinuation syndrome
Last edited 05/2018
- Prevention
- Tapering after successful treatment
- Recommendations on taper length vary
- has been suggested that antidepressants administered for 8 weeks or more should, wherever possible, be reduced over a 4-week period
- NICE suggest that
- normally, gradually reduce the dose over 4 weeks (this is
not necessary with fluoxetine). Reduce the dose over longer
periods for drugs with a shorter half-life (for example, paroxetine
and venlafaxine)
- normally, gradually reduce the dose over 4 weeks (this is
not necessary with fluoxetine). Reduce the dose over longer
periods for drugs with a shorter half-life (for example, paroxetine
and venlafaxine)
- routine tapering is probably unnecessary when antidepressants have been prescribed for less than 4 weeks, as discontinuation symptoms are unlikely to occur with such a short duration of treatment (2)
- an abruption of an antidepressant is justified if a patient has
developed serious side effects believed to be due to the antidepressant,
there is a medical emergency warranting stopping the antidepressant
or the antidepressant has induced mania (2)
- Recommendations on taper length vary
- Tapering and antidepressant switching
- data imply that if tapering SSRIs and venlafaxine is beneficial in reducing discontinuation symptoms, then it needs to continue for more than 14 days for most patients.
- a start-taper switch refers to starting the new antidepressant and
simultaneously gradually tapering the previous one
- whether an abrupt switch or start-taper switch is chosen partly depends on the likelihood of discontinuation symptoms occurring, which in turn depends on the pharmacological similarity between the two antidepressants
- using a washout period (no antidepressant prescribed)
- is essential when switching to and from MAOIs because of the risk of drug interactions that can lead to serotonin syndrome
- a washout should also be considered when switching from fluoxetine
to a TCA, as the long-half life of fluoxetine, plus its ability
to inhibit cytochrome P450 enzymes, could result in elevation
of plasma TCA levels, leading to adverse effects (2)
- Tapering after successful treatment
Reference:
- Renoir T. Selective Serotonin Reuptake Inhibitor Antidepressant Treatment Discontinuation Syndrome: A Review of the Clinical Evidence and the Possible Mechanisms Involved. Front Pharmacol. 2013; 4: 45.
- Haddad PM, Anderson IM. Advances in Psychiatric Treatment 2007; 13: 447-457
- Haddad, PMThe SSRI discontinuation syndrome. Journal of Psychopharmacology 1998; 12: 305-313.
- Tint, A., Haddad, P. M, Anderson, I. M. The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. Journal of Psychopharmacology 2007
- NICE (October 2009). Depression